Literature DB >> 33043466

Psychometric longitudinal evaluation of the Chronic Acquired Polyneuropathy Patient-Reported Index (CAPPRI) in patients with chronic inflammatory demyelinating polyneuropathy.

Reza Sadjadi1, Stojan Peric2, Kelly Gwathmey3, Ivo Bozovic2, Palibrk Aleksa2, Bogdan Bjelica2, Ted Burns4, Ivana Basta2.   

Abstract

BACKGROUND: We studied the performance of a 15-item, health-related quality-of-life polyneuropathy scale in a longitudinal study of patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
METHODS: Sixty-one patients with CIDP completed the Chronic Acquired Polyneuropathy Patient-Reported Index (CAPPRI) scale and Patient Impression of Change (PIC) at baseline and follow-up visits. Clinicians completed Inflammatory Neuropathy Cause and Treatment (INCAT) disability scores at baseline and follow-up visits. Conventional and modern psychometric analyses were performed on the completed forms.
RESULTS: CAPPRI was psychometrically stable between visits without significant difference in response pattern between visits 1 and 2 (paired t-test P = .72). There was strong correlation between changes in INCAT and changes in CAPPRI scores between two visits (rho = 0.6, P < .001). In addition, we showed robust CAPPRI effect sizes between PIC categories.
CONCLUSIONS: We demonstrated psychometric stability and construct longitudinal validity of CAPPRI.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  Rasch analysis; chronic inflammatory demyelinating polyneuropathy; longitudinal; outcome measures; psychometrics

Year:  2020        PMID: 33043466     DOI: 10.1002/mus.27089

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  2 in total

1.  Prospective analysis of disability and quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Ivo Bozovic; Marina Peric; Ana Arsic Azanjac; Aleksa Palibrk; Ivana Bulatovic; Dejan Aleksic; Stojan Peric; Ivana Basta
Journal:  Qual Life Res       Date:  2021-04-08       Impact factor: 4.147

2.  Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.

Authors:  S R M Bus; M C Broers; F Eftimov; I M Lucke; C Bunschoten; G G A van Lieverloo; M E Adrichem; R van Veen; L Wieske; H F Lingsma; H S Goedee; W L van der Pol; I N van Schaik; P A Van Doorn; B C Jacobs
Journal:  J Neurol       Date:  2021-06-26       Impact factor: 6.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.